EA200800451A1 - Лечение дигидропиридиновыми блокаторами кальциевых каналов и жирными кислотами омега-3 и их комбинированным продуктом - Google Patents

Лечение дигидропиридиновыми блокаторами кальциевых каналов и жирными кислотами омега-3 и их комбинированным продуктом

Info

Publication number
EA200800451A1
EA200800451A1 EA200800451A EA200800451A EA200800451A1 EA 200800451 A1 EA200800451 A1 EA 200800451A1 EA 200800451 A EA200800451 A EA 200800451A EA 200800451 A EA200800451 A EA 200800451A EA 200800451 A1 EA200800451 A1 EA 200800451A1
Authority
EA
Eurasian Patent Office
Prior art keywords
omega
dihydropyridine
blockers
treatment
fatty acids
Prior art date
Application number
EA200800451A
Other languages
English (en)
Inventor
Джордж Боботас
Рулоф М. Л. Ронген
Original Assignee
Релайэнт Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Релайэнт Фармасьютикалз, Инк. filed Critical Релайэнт Фармасьютикалз, Инк.
Publication of EA200800451A1 publication Critical patent/EA200800451A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Комбинации одного или нескольких дигидропиридиновых блокаторов кальциевых каналов со смесями омега-3 жирных кислот, способы введения таких комбинаций и стандартные лекарственные формы таких комбинаций.
EA200800451A 2005-07-28 2006-07-28 Лечение дигидропиридиновыми блокаторами кальциевых каналов и жирными кислотами омега-3 и их комбинированным продуктом EA200800451A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70300205P 2005-07-28 2005-07-28
PCT/US2006/029217 WO2007016256A2 (en) 2005-07-28 2006-07-28 Treatment with dihydropyridine calcium channel blockers and omega-3 fatty acids and a combination product thereof

Publications (1)

Publication Number Publication Date
EA200800451A1 true EA200800451A1 (ru) 2008-08-29

Family

ID=37709175

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200800451A EA200800451A1 (ru) 2005-07-28 2006-07-28 Лечение дигидропиридиновыми блокаторами кальциевых каналов и жирными кислотами омега-3 и их комбинированным продуктом

Country Status (12)

Country Link
US (1) US20070196465A1 (ru)
EP (1) EP1919285A2 (ru)
JP (1) JP2009502950A (ru)
KR (1) KR20080030691A (ru)
CN (1) CN101252837A (ru)
AU (1) AU2006275784A1 (ru)
BR (1) BRPI0614417A2 (ru)
CA (1) CA2616806A1 (ru)
EA (1) EA200800451A1 (ru)
MX (1) MX2008001282A (ru)
NO (1) NO20081067L (ru)
WO (1) WO2007016256A2 (ru)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8784886B2 (en) * 2006-03-09 2014-07-22 GlaxoSmithKline, LLC Coating capsules with active pharmaceutical ingredients
EP2081550B2 (en) * 2006-03-09 2021-05-26 Reliant Pharmaceuticals, Inc. Coating capsules with active pharmaceutical ingredients
EP3050568B1 (en) 2007-03-13 2020-12-02 JDS Therapeutics, LLC Methods and compositions for the sustained release of chromium
WO2009002867A2 (en) 2007-06-26 2008-12-31 Nutrition 21, Inc. Multiple unit dosage form having a therapeutic agents in combination with a nutritional supplement
US20100113534A1 (en) * 2008-08-01 2010-05-06 Rajeshwar Motheram Pharmaceutical Compositions And Methods For Producing Low Impurity Concentrations Of The Same
EP2320739B1 (en) * 2008-08-01 2019-11-27 Chiesi Farmaceutici S.p.A. Pharmaceutical compositions and methods for stabilizing the same
ES2862336T3 (es) 2008-09-02 2021-10-07 Amarin Pharmaceuticals Ie Ltd Composición farmacéutica que comprende ácido eicosapentaenoico y ácido nicotínico y métodos de uso de la misma
LT3037089T (lt) 2009-02-10 2020-01-10 Amarin Pharmaceuticals Ireland Limited Eikozapentaeno rūgšties etilo esteris skirtas hipertriglicidemijai gydydti
CN106822080A (zh) 2009-04-29 2017-06-13 阿马里纳药物爱尔兰有限公司 含有epa和心血管剂的药物组合物以及使用其的方法
CN102458109B (zh) 2009-04-29 2015-02-11 阿马里纳制药公司 稳定的药物组合物和使用其的方法
SG10201708950XA (en) 2009-06-15 2017-12-28 Ian Osterloh Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
AU2010298222B2 (en) 2009-09-23 2017-01-05 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same
ES2363964B1 (es) 2009-11-20 2012-08-22 Gp Pharm, S.A. Cápsulas de principios activos farmacéuticos y ésteres de ácidos grasos poliinsaturados.
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
WO2012074930A2 (en) 2010-11-29 2012-06-07 Amarin Pharma, Inc. Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US8951514B2 (en) 2011-02-16 2015-02-10 Pivotal Therapeutics Inc. Statin and omega 3 fatty acids for reduction of apolipoprotein-B levels
US8952000B2 (en) 2011-02-16 2015-02-10 Pivotal Therapeutics Inc. Cholesterol absorption inhibitor and omega 3 fatty acids for the reduction of cholesterol and for the prevention or reduction of cardiovascular, cardiac and vascular events
US8715648B2 (en) 2011-02-16 2014-05-06 Pivotal Therapeutics Inc. Method for treating obesity with anti-obesity formulations and omega 3 fatty acids for the reduction of body weight in cardiovascular disease patients (CVD) and diabetics
US9119826B2 (en) 2011-02-16 2015-09-01 Pivotal Therapeutics, Inc. Omega 3 fatty acid for use as a prescription medical food and omega 3 fatty acid diagniostic assay for the dietary management of cardiovascular patients with cardiovascular disease (CVD) who are deficient in blood EPA and DHA levels
KR101310710B1 (ko) * 2011-03-23 2013-09-27 한미약품 주식회사 오메가-3 지방산 에스테르 및 ＨＭＧ-ＣｏＡ 환원효소 억제제를 포함하는 경구용 복합 조성물
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
US20130131170A1 (en) 2011-11-07 2013-05-23 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
EP2800469B1 (en) 2012-01-06 2021-08-25 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering levels of high-sensitivity (hs-crp) in a subject
AU2013277441B2 (en) 2012-06-17 2017-07-06 Matinas Biopharma, Inc. Omega-3 pentaenoic acid compositions and methods of use
JP2015522029A (ja) 2012-06-29 2015-08-03 アマリン ファーマシューティカルス アイルランド リミテッド スタチン療法中の患者における心血管系イベントの危険性を減少させる方法
WO2014074552A2 (en) 2012-11-06 2014-05-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9814733B2 (en) 2012-12-31 2017-11-14 A,arin Pharmaceuticals Ireland Limited Compositions comprising EPA and obeticholic acid and methods of use thereof
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9662307B2 (en) 2013-02-19 2017-05-30 The Regents Of The University Of Colorado Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
US9283201B2 (en) 2013-03-14 2016-03-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating or preventing obesity in a subject in need thereof
US20140271841A1 (en) 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US10966968B2 (en) 2013-06-06 2021-04-06 Amarin Pharmaceuticals Ireland Limited Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
US20150065572A1 (en) 2013-09-04 2015-03-05 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing prostate cancer
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
US10561631B2 (en) 2014-06-11 2020-02-18 Amarin Pharmaceuticals Ireland Limited Methods of reducing RLP-C
WO2015195662A1 (en) 2014-06-16 2015-12-23 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids
GB2564295A (en) 2016-02-11 2019-01-09 Nutrition 21 Llc Chromium containing compositions for improving health and fitness
US10406130B2 (en) 2016-03-15 2019-09-10 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
WO2018213663A1 (en) 2017-05-19 2018-11-22 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject having reduced kidney function
US11058661B2 (en) 2018-03-02 2021-07-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
CN112218630A (zh) 2018-09-24 2021-01-12 阿马里纳药物爱尔兰有限公司 降低受试者的心血管事件的风险的方法
WO2022225896A1 (en) 2021-04-21 2022-10-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of heart failure

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8819110D0 (en) * 1988-08-11 1988-09-14 Norsk Hydro As Antihypertensive drug & method for production
US5186942A (en) * 1989-01-30 1993-02-16 Alza Corporation Nicardipine therapy
US5162325A (en) * 1991-05-07 1992-11-10 Merck & Co., Inc. Angiotensin ii antagonists incorporating a substituted benzyl element
DE4322826A1 (de) * 1993-07-08 1995-01-12 Galenik Labor Freiburg Gmbh Pharmazeutisches Präparat
TW483763B (en) * 1994-09-02 2002-04-21 Astra Ab Pharmaceutical composition comprising of ramipril and dihydropyridine compound
AR032643A1 (es) * 2001-01-26 2003-11-19 Schering Corp Combinaciones de inhibidor(es) de absorcion de esterol con agente(s) cardiovascular(es) para el tratamiento de condiciones vasculares
JP4421804B2 (ja) * 2002-03-25 2010-02-24 日本メナード化粧品株式会社 高血圧抑制剤
US7759507B2 (en) * 2003-09-05 2010-07-20 Abbott Laboratories Lipid system and methods of use
US8784886B2 (en) * 2006-03-09 2014-07-22 GlaxoSmithKline, LLC Coating capsules with active pharmaceutical ingredients

Also Published As

Publication number Publication date
US20070196465A1 (en) 2007-08-23
KR20080030691A (ko) 2008-04-04
JP2009502950A (ja) 2009-01-29
WO2007016256A3 (en) 2007-07-12
CA2616806A1 (en) 2007-02-08
AU2006275784A1 (en) 2007-02-08
BRPI0614417A2 (pt) 2011-03-29
WO2007016256A2 (en) 2007-02-08
CN101252837A (zh) 2008-08-27
EP1919285A2 (en) 2008-05-14
MX2008001282A (es) 2008-03-24
NO20081067L (no) 2008-04-18

Similar Documents

Publication Publication Date Title
EA200800451A1 (ru) Лечение дигидропиридиновыми блокаторами кальциевых каналов и жирными кислотами омега-3 и их комбинированным продуктом
EA200970374A1 (ru) Лечение антиаритмическими средствами и омега-3 жирными кислотами и их комбинированным продуктом
EA200800356A1 (ru) Лечение ингибиторами абсорбции холестерина на основе азетидинона и омега-3 жирными кислотами и их комбинированным препаратом
NO20076687L (no) Oral doseringsform
EA201170508A1 (ru) Производные 1-амино-2-циклобутилэтилбороновой кислоты
EA201170036A1 (ru) Соединения боронатного эфира и его фармацевтические составы
EA201190217A1 (ru) Замещенные 2-ацетамидо-5-арил-1,2,4-триазолоны и их применение
CL2008003848A1 (es) Compuestos derivados de fenilo o heteroarilo bis-sulfonilamino sustituidos, inhibidores de prostaglandina e sintasa-1 microsomal; composicion farmaceutica; procedimiento de preparacion; procedimiento de preparacion de la composicion farmaceutica; y uso en el tratamiento del dolor agudo o cronico, dolor nociceptivo o dolor neuropatico.
DK1970059T3 (da) Lægemiddel med calciumdobesilat til behandling og profylakse af senelidelser
EA200901032A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
EA201171403A1 (ru) Устойчивые оральные фармацевтические дозированные формы, содержащие опиоидный анальгетик
EA201001329A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
EA201001847A1 (ru) Соединения и композиции, применяемые для лечения малярии
EA201100138A1 (ru) 4-феноксиметилпиперидины в качестве модуляторов активности gpr119
EA201001332A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
CO6551683A2 (es) Tratamiento para trastornos gastrointestinales
EA200970483A1 (ru) Применение пролекарств габапентина и прегабалина для лечения шума в ушах
EA200701820A1 (ru) Применение диосметиновых соединений при лечении и профилактике тромботических патологий
EA200802324A1 (ru) Новая форма введения рацекадотрила
EA201001288A1 (ru) Лечение гипертонии 25-гидроксивитамином d3
EA201001330A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
EA200801580A1 (ru) Новые производные пирониндола и способ их получения
CY1117184T1 (el) ΤΕΛΕΣΤΕΣ β-ΑΡΡΕΣΤΙΝΗΣ ΚΑΙ ΣΥΝΘΕΣΕΙΣ ΚΑΙ ΜΕΘΟΔΟΙΧΡΗΣΗΣ ΑΥΤΩΝ
TW200734306A (en) Novel compounds, their preparation and use
EA201391407A1 (ru) Композиции для лечения нервных расстройств